The estimated Net Worth of Matthew Malenfant is at least $1.93 Millón dollars as of 1 September 2022. Mr. Malenfant owns over 27,040 units of Covetrus stock worth over $1,929,716 and over the last 4 years he sold CVET stock worth over $0. In addition, he makes $0 as President y Customer Operations - North America at Covetrus.
Matthew has made over 5 trades of the Covetrus stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 27,040 units of CVET stock worth $567,570 on 1 September 2022.
The largest trade he's ever made was exercising 27,040 units of Covetrus stock on 1 September 2022 worth over $567,570. On average, Matthew trades about 7,733 units every 47 days since 2020. As of 1 September 2022 he still owns at least 91,935 units of Covetrus stock.
You can see the complete history of Mr. Malenfant stock trades at the bottom of the page.
Matthew C. Malenfant has been appointed as President, Customer Operations - North America of the Company effective 5/18/2020. He most recently served as the Executive Chairman of DWK Life Sciences, LLC, a manufacturer of precision glassware, laboratory consumables, pharmaceutical packaging and specialty life science products, from 2019 to 2020. From 2018 through the present, Mr. Malenfant served as the Principal of Malenfant Consulting, LLC., a leadership coaching and organizational design company. He previously served as the Chief Executive Officer of Saxco International, LLC, a packaging distributor for the spirits, wine and beer industries, from 2012 through 2017. Mr. Malenfant received his Master's from Merck University and his BA/BS from Arizona State University.
Matthew Malenfant is 58, he's been the President y Customer Operations - North America of Covetrus since 2020. There are 8 older and 18 younger executives at Covetrus. The oldest executive at Covetrus, Inc. is Philip Laskawy, 78, who is the Independent Chairman of the Board.
Matthew's mailing address filed with the SEC is 7, Custom House Street, India Street, Portland, Cumberland County, Maine, 04101, United States.
Over the last 5 years, insiders at Covetrus have traded over $10,243,394 worth of Covetrus stock and bought 11,744 units worth $216,180 . The most active insiders traders include Steven Paladino, Benjamin Wolin y Philip A Laskawy. On average, Covetrus executives and independent directors trade stock every 10 days with the average trade being worth of $268,798. The most recent stock trade was executed by Rebecca Ann Kidd on 1 October 2022, trading 1,232 units of CVET stock currently worth $25,860.
Covetrus, Inc., together with its subsidiaries, operates as an animal-health technology and services company. It engages in the sale of animal-health consumable products, including proprietary and Covetrus branded products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, parasiticides, and vitamins and supplements to wholesale and retail customers. The company also offers value-added solutions that include, inventory management and e-commerce, as well as continuing education services for practitioners. In addition, it provides practice management software systems for veterinary practitioners and animal-health clinics, client communication services, reminders, data backup services, and hardware sales and support services. Further, the company engages in the distribution of finished goods pharmacy and specialty pharmaceutical compounding products, as well as shipping, manufacturer incentives, service fees, and data integration and support services. It serves animal-health and veterinary practices, and clinics in the companion-animal and equine markets primarily in North America, Europe, and the Asia Pacific. The company was formerly known as HS Spinco, Inc. Covetrus, Inc. was incorporated in 2018 and is headquartered in Portland, Maine.
Covetrus executives and other stock owners filed with the SEC include: